For pharma IP teams, portfolio managers, R&D leads, and institutional investors navigating the post-IRA, outcomes-contingent revenue landscape. The numbers are […]
Biopharma Sales Forecasting in the Value-Based Era: The Complete Analyst’s Playbook Read Post »
A drug patent is not a legal document. It is a financial instrument — one whose value fluctuates from zero
Drug Patent Valuation: The 8-Factor Framework That Separates $50M Assets from $50B Ones Read Post »
The global biopharmaceutical deal machine ran at record velocity in 2024. China’s out-licensing deal value hit an estimated $47 billion,
Every year, pharmaceutical companies forfeit billions in recoverable IP value not because their science failed, but because their patent strategy
US vs EU Pharma Patent Strategy: The Complete Competitive Intelligence Guide Read Post »
Between 2025 and 2030, an estimated $200-300 billion in branded drug sales globally will lose patent protection. That figure covers
Pharma Patent Cliff Models That Actually Predict Stock Performance Read Post »
The average capitalized cost to develop a new drug now exceeds $2.23 billion. The effective market exclusivity that investment buys,
Drug Patent Portfolio ROI: The Complete Optimization Playbook for Pharma IP Teams Read Post »
The loss of exclusivity for a blockbuster biologic is no longer a theoretical risk management exercise. It is a discrete,
Every year, pharmaceutical companies quietly authorize hundreds of millions of dollars in new formulation work before a single press release
The Bayh-Dole Act of 1980 is arguably the single most consequential piece of legislation in the history of American biomedical
Get fresh news and insights, drug patent expirations & more…
